Obesity as a risk factor in cancer: A national consensus of the Spanish Society for the Study of Obesity and the Spanish Society of Medical Oncology

Abstract

In the last few years, many prospective studies have demonstrated a clear association between obesity and cancers of the colon and rectum, breast in post-menopausal women, endometrium, kidney, oesophagus and pancreas. Obesity is also associated with a high risk of recurrence and cancer-related death. The pathophysiology of obesity involves various changes that may be implicated in the relationship between obesity and cancer, such as excess inflammatory cytokines and chronic inflammation, hyperinsulinaemia, insulin resistance, and raised leptin and oestrogens. The Spanish Society for the Study of Obesity and the Spanish Society of Medical Oncology have signed a cooperation agreement to work together towards reducing the impact of obesity in cancer. Preventing obesity prevents cancer.

A Comprehensive Comparison of LRYGB and LSG in Obese Patients Including the Effects on QoL, Comorbidities, Weight Loss, and Complications: a Systematic Review and Meta-Analysis

“…Inclusion criteria are as follows: (1) sample size of every group > 15 patients; (2) human study reported in English; (3) at least one of the following endpoints was included: early complications, resolution rate of comorbidities, and weight loss (performed as EWL%); (4) patient ages ranged from 18 to 70 years old; (5) comparative studies between LRYGB and LSG. Exclusion criteria are as follows: (1) non-human studies;…”

“…With its increasing prevalence, obesity has become a global public health problem over the past few decades [1]. Being overweight is accepted as a risk factor for serious health issues, such as type 2 diabetes, hypertension, diseases, or even cancers [2][3][4]. Compared with various strategies, including medications, behavior changes, and diet therapy, bariatric Electronic supplementary material The online version of this article (https://doi.org/10.1007/s11695-019-04306-4) contains supplementary material, which is available to authorized users.…”

Propofol Disrupts Aerobic Glycolysis in Colorectal Cancer Cells via Inactivation of the NMDAR-CAMKII-ERK Pathway

“…Despite advances in neoadjuvant therapy, the 5-year relative survival rate for colorectal cancer remains at less than 50% in low-income countries. Epidemiological studies have consistently shown an interaction between the risk of colorectal cancer and various factors, such as inflammatory bowel disease [6], obesity [7], excessive alcohol consumption [8], and diabetes [9]. Although genome-wide association studies have identified multiple factors related to the progression of colorectal cancer, the molecular mechanisms underlying its development are still understood poorly.…”

Adherencia y tolerancia como claves en la detención de la pérdida de peso en pacientes oncológicos sometidos a radioterapia mediante una estrategia de suplementación precoz con una fórmula enteral hipercalórica e hiperproteica específica

“…Con el objetivo de informar a los profesionales y a la población sobre la importancia de ello, la SEOM y la Sociedad Española para el Estudio de la Obesidad (SEEDO) firmaron un acuerdo de colaboración en julio del 2014 para desarrollar conjuntamente el proyecto OBEyCAN y se publicó el primer Consenso Nacional sobre la Obesidad como factor de riesgo (26). Los datos publicados en la actualidad reflejan, además, que los pacientes con cáncer y con un IMC alto tienen una peor tolerancia a los tratamientos oncológicos y más posibilidades de recaer o de padecer un segundo tumor (27,28).…”